{"status":"ok","message-type":"work","message-version":"1.0.0","message":{"indexed":{"date-parts":[[2026,11,4]],"date-time":"2026-11-04T12:34:34Z","timestamp":1793795674571,"version":"4.6.1"},"reference-count":79,"publisher":"Elsevier BV","license":[{"start":{"date-parts":[[2018,9,1]],"date-time":"2018-09-01T00:00:00Z","timestamp":1535760000000},"content-version":"tdm","delay-in-days":0,"URL":"https:\/\/www.elsevier.com\/tdm\/userlicense\/1.0\/"}],"funder":[{"DOI":"10.13039\/100001605","name":"Epilepsy Foundation","doi-asserted-by":"publisher","id":[{"id":"10.13039\/100001605","id-type":"DOI","asserted-by":"publisher"}]}],"content-domain":{"domain":["elsevier.com","sciencedirect.com"],"crossmark-restriction":true},"short-container-title":["Neuropharmacology"],"published-print":{"date-parts":[[2018,9]]},"DOI":"10.1016\/j.neuropharm.2018.08.002","type":"journal-article","created":{"date-parts":[[2018,8,3]],"date-time":"2018-08-03T16:47:40Z","timestamp":1533314860000},"page":"107-120","update-policy":"https:\/\/doi.org\/10.1016\/elsevier_cm_policy","source":"Crossref","is-referenced-by-count":78,"special_numbering":"C","title":["The novel, catalytic mTORC1\/2 inhibitor PQR620 and the PI3K\/mTORC1\/2 inhibitor PQR530 effectively cross the blood-brain barrier and increase seizure threshold in a mouse model of chronic epilepsy"],"prefix":"10.1016","volume":"140","author":[{"given":"Claudia","family":"Brandt","sequence":"first","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Petra","family":"Hillmann","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Andreas","family":"Noack","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Kerstin","family":"R\u00f6mermann","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Leon A.","family":"\u00d6hler","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Denise","family":"Rageot","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Florent","family":"Beaufils","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Anna","family":"Melone","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Alexander M.","family":"Sele","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Matthias P.","family":"Wymann","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Doriano","family":"Fabbro","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Wolfgang","family":"L\u00f6scher","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]}],"member":"78","reference":[{"key":"10.1016\/j.neuropharm.2018.08.002_bib1","doi-asserted-by":"crossref","first-page":"569","DOI":"10.1002\/ana.23943","article-title":"TORC1-dependent epilepsy caused by acute biallelic Tsc1 deletion in adult mice","volume":"74","author":"Abs","year":"2013","journal-title":"Ann. Neurol."},{"key":"10.1016\/j.neuropharm.2018.08.002_bib2","doi-asserted-by":"crossref","first-page":"142","DOI":"10.1016\/0920-1211(91)90006-2","article-title":"Evidence for the interaction of brainstem systems mediating seizure expression in kindling and electroconvulsive shock seizure models","volume":"10","author":"Applegate","year":"1991","journal-title":"Epilepsy Res."},{"key":"10.1016\/j.neuropharm.2018.08.002_bib3","doi-asserted-by":"crossref","first-page":"205","DOI":"10.1016\/j.eplepsyres.2013.09.014","article-title":"Pilocarpine-induced epilepsy in mice alters seizure thresholds and the efficacy of antiepileptic drugs in the 6-Hertz psychomotor seizure model","volume":"107","author":"Bankstahl","year":"2013","journal-title":"Epilepsy Res."},{"key":"10.1016\/j.neuropharm.2018.08.002_bib4","first-page":"393A","article-title":"Pharmacological characterization of the selective, orally bioavailable, potent mTORC1\/2 inhibitor PQR620","volume":"vol. 76","author":"Beaufils","year":"2016"},{"key":"10.1016\/j.neuropharm.2018.08.002_bib5","first-page":"1336","article-title":"Structure-activity relationship studies, synthesis, and biological evaluation of PQR620, a highly potent and selective mTORC1\/2 inhibitor","volume":"vol. 76","author":"Beaufils","year":"2016"},{"key":"10.1016\/j.neuropharm.2018.08.002_bib6","doi-asserted-by":"crossref","first-page":"7254","DOI":"10.1021\/acs.jmedchem.7b00930","article-title":"5-(4,6-Dimorpholino-1,3,5-triazin-2-yl)-4-(trifluoromethyl)pyridin-2-amine (PQR309), a potent, brain-penetrant, orally bioavailable, pan-class I PI3K\/mTOR inhibitor as clinical candidate in oncology","volume":"60","author":"Beaufils","year":"2017","journal-title":"J. Med. Chem."},{"key":"10.1016\/j.neuropharm.2018.08.002_bib7","doi-asserted-by":"crossref","first-page":"3481","DOI":"10.1002\/cncr.29422","article-title":"A phase I dose-escalation study to assess safety, tolerability, pharmacokinetics, and preliminary efficacy of the dual mTORC1\/mTORC2 kinase inhibitor CC-223 in patients with advanced solid tumors or multiple myeloma","volume":"121","author":"Bendell","year":"2015","journal-title":"Cancer"},{"key":"10.1016\/j.neuropharm.2018.08.002_bib8","doi-asserted-by":"crossref","first-page":"824","DOI":"10.1111\/j.1528-1167.2008.01797.x","article-title":"Assessment of seizure susceptibility in pilocarpine epileptic and nonepileptic Wistar rats and of seizure reinduction with pentylenetetrazole and electroshock models","volume":"50","author":"Blanco","year":"2009","journal-title":"Epilepsia"},{"key":"10.1016\/j.neuropharm.2018.08.002_bib9","doi-asserted-by":"crossref","DOI":"10.1371\/journal.pone.0057808","article-title":"Rapamycin reverses status epilepticus-induced memory deficits and dendritic damage","volume":"8","author":"Brewster","year":"2013","journal-title":"PLoS One"},{"key":"10.1016\/j.neuropharm.2018.08.002_bib10","doi-asserted-by":"crossref","first-page":"2337","DOI":"10.1523\/JNEUROSCI.4852-10.2011","article-title":"Rapamycin suppresses mossy fiber sprouting but not seizure frequency in a mouse model of temporal lobe epilepsy","volume":"31","author":"Buckmaster","year":"2011","journal-title":"J. Neurosci."},{"key":"10.1016\/j.neuropharm.2018.08.002_bib11","doi-asserted-by":"crossref","first-page":"101","DOI":"10.1358\/mf.2009.31.2.1338414","article-title":"The maximal electroshock seizure (MES) model in the preclinical assessment of potential new antiepileptic drugs","volume":"31","author":"Castel-Branco","year":"2009","journal-title":"Methods Find. Exp. Clin. Pharmacol."},{"key":"10.1016\/j.neuropharm.2018.08.002_bib12","doi-asserted-by":"crossref","first-page":"2015","DOI":"10.1111\/j.1528-1167.2012.03674.x","article-title":"Rapamycin has age-, treatment paradigm-, and model-specific anticonvulsant effects and modulates neuropeptide Y expression in rats","volume":"53","author":"Chachua","year":"2012","journal-title":"Epilepsia"},{"key":"10.1016\/j.neuropharm.2018.08.002_bib13","doi-asserted-by":"crossref","first-page":"127","DOI":"10.1016\/j.brainresbull.2006.08.009","article-title":"Drug resistance and hippocampal damage after delayed treatment of pilocarpine-induced epilepsy in the rat","volume":"71","author":"Chakir","year":"2006","journal-title":"Brain Res. Bull."},{"key":"10.1016\/j.neuropharm.2018.08.002_bib14","doi-asserted-by":"crossref","first-page":"333","DOI":"10.1016\/j.phrs.2016.03.039","article-title":"mTOR pathway inhibition as a new therapeutic strategy in epilepsy and epileptogenesis","volume":"107","author":"Citraro","year":"2016","journal-title":"Pharmacol. Res."},{"key":"10.1016\/j.neuropharm.2018.08.002_bib15","doi-asserted-by":"crossref","first-page":"2415","DOI":"10.1007\/s12035-016-9827-0","article-title":"KU0063794, a dual mTORC1 and mTORC2 inhibitor, reduces neural tissue damage and locomotor impairment after spinal cord injury in mice","volume":"54","author":"Cordaro","year":"2017","journal-title":"Mol. Neurobiol."},{"key":"10.1016\/j.neuropharm.2018.08.002_bib16","doi-asserted-by":"crossref","first-page":"379","DOI":"10.1038\/nrneurol.2016.81","article-title":"The mTOR signalling cascade: paving new roads to cure neurological disease","volume":"12","author":"Crino","year":"2016","journal-title":"Nat. Rev. Neurol."},{"key":"10.1016\/j.neuropharm.2018.08.002_bib17","doi-asserted-by":"crossref","first-page":"143","DOI":"10.1016\/j.jneumeth.2008.04.019","article-title":"The pilocarpine model of temporal lobe epilepsy","volume":"172","author":"Curia","year":"2008","journal-title":"J. Neurosci. Meth."},{"key":"10.1016\/j.neuropharm.2018.08.002_bib18","doi-asserted-by":"crossref","first-page":"1046","DOI":"10.1038\/nbt.1990","article-title":"Comprehensive analysis of kinase inhibitor selectivity","volume":"29","author":"Davis","year":"2011","journal-title":"Nat. Biotechnol."},{"key":"10.1016\/j.neuropharm.2018.08.002_bib19","doi-asserted-by":"crossref","first-page":"688","DOI":"10.1111\/epi.13345","article-title":"Effects of rapamycin and curcumin treatment on the development of epilepsy after electrically induced status epilepticus in rats","volume":"57","author":"Drion","year":"2016","journal-title":"Epilepsia"},{"key":"10.1016\/j.neuropharm.2018.08.002_bib20","doi-asserted-by":"crossref","first-page":"843","DOI":"10.1038\/nm1788","article-title":"Reversal of learning deficits in a Tsc2+\/- mouse model of tuberous sclerosis","volume":"14","author":"Ehninger","year":"2008","journal-title":"Nat. Med."},{"key":"10.1016\/j.neuropharm.2018.08.002_bib21","doi-asserted-by":"crossref","first-page":"698","DOI":"10.1111\/epi.13346","article-title":"The bumetanide prodrug BUM5, but not bumetanide, potentiates the antiseizure effect of phenobarbital in adult epileptic mice","volume":"57","author":"Erker","year":"2016","journal-title":"Epilepsia"},{"key":"10.1016\/j.neuropharm.2018.08.002_bib22","doi-asserted-by":"crossref","first-page":"2153","DOI":"10.1016\/S0140-6736(16)31419-2","article-title":"Adjunctive everolimus therapy for treatment-resistant focal-onset seizures associated with tuberous sclerosis (EXIST-3): a phase 3, randomised, double-blind, placebo-controlled study","volume":"388","author":"French","year":"2016","journal-title":"Lancet"},{"key":"10.1016\/j.neuropharm.2018.08.002_bib23","doi-asserted-by":"crossref","first-page":"1119","DOI":"10.1111\/j.1528-1167.2012.03506.x","article-title":"Finding a better drug for epilepsy: the mTOR pathway as an antiepileptogenic target","volume":"53","author":"Galanopoulou","year":"2012","journal-title":"Epilepsia"},{"key":"10.1016\/j.neuropharm.2018.08.002_bib24","doi-asserted-by":"crossref","first-page":"3243","DOI":"10.1007\/s00018-012-1206-z","article-title":"Functional diversity and pharmacological profiles of the FKBPs and their complexes with small natural ligands","volume":"70","author":"Galat","year":"2013","journal-title":"Cell. Mol. Life Sci."},{"key":"10.1016\/j.neuropharm.2018.08.002_bib25","doi-asserted-by":"crossref","first-page":"169","DOI":"10.1016\/j.npep.2009.12.007","article-title":"Akt pathway activation and increased neuropeptide Y mRNA expression in the rat hippocampus: implications for seizure blockade","volume":"44","author":"Goto","year":"2010","journal-title":"Neuropeptides"},{"key":"10.1016\/j.neuropharm.2018.08.002_bib26","doi-asserted-by":"crossref","first-page":"329","DOI":"10.1016\/j.expneurol.2007.06.021","article-title":"Behavioral alterations in the pilocarpine model of temporal lobe epilepsy in mice","volume":"207","author":"Gr\u00f6ticke","year":"2007","journal-title":"Exp. Neurol."},{"key":"10.1016\/j.neuropharm.2018.08.002_bib27","doi-asserted-by":"crossref","DOI":"10.1371\/journal.pone.0045156","article-title":"The mTOR inhibitor rapamycin has limited acute anticonvulsant effects in mice","volume":"7","author":"Hartman","year":"2012","journal-title":"PLoS One"},{"key":"10.1016\/j.neuropharm.2018.08.002_bib28","doi-asserted-by":"crossref","first-page":"1535","DOI":"10.1111\/epi.12246","article-title":"High-dose rapamycin blocks mossy fiber sprouting but not seizures in a mouse model of temporal lobe epilepsy","volume":"54","author":"Heng","year":"2013","journal-title":"Epilepsia"},{"key":"10.1016\/j.neuropharm.2018.08.002_bib29","series-title":"Proceedings of the 107th Annual Meeting of the American Association for Cancer Research; 2017, Washington, DC","article-title":"Pharmacological characterization of the selective, orally bioavailable, potent dual PI3K\/mTORC1\/2 inhibitor PQR530","author":"Hillmann","year":"2017"},{"key":"10.1016\/j.neuropharm.2018.08.002_bib30","doi-asserted-by":"crossref","first-page":"193","DOI":"10.1016\/j.nbd.2010.05.024","article-title":"Pharmacological inhibition of the mammalian target of rapamycin pathway suppresses acquired epilepsy","volume":"40","author":"Huang","year":"2010","journal-title":"Neurobiol. Dis."},{"key":"10.1016\/j.neuropharm.2018.08.002_bib31","doi-asserted-by":"crossref","first-page":"205","DOI":"10.1038\/nm.2091","article-title":"Effective and selective targeting of leukemia cells using a TORC1\/2 kinase inhibitor","volume":"16","author":"Janes","year":"2010","journal-title":"Nat. Med."},{"key":"10.1016\/j.neuropharm.2018.08.002_bib32","first-page":"855","article-title":"Hyperglycemia and phosphatidylinositol 3-kinase\/protein kinase B\/Mammalian target of rapamycin (PI3K\/AKT\/mTOR) inhibitors in phase I trials: incidence, predictive factors, and management","volume":"21","author":"Khan","year":"2016","journal-title":"Oncology"},{"key":"10.1016\/j.neuropharm.2018.08.002_bib33","doi-asserted-by":"crossref","first-page":"1055","DOI":"10.1517\/14740338.2015.1040388","article-title":"Everolimus and sirolimus in transplantation-related but different","volume":"14","author":"Klawitter","year":"2015","journal-title":"Expet Opin. Drug Saf."},{"key":"10.1016\/j.neuropharm.2018.08.002_bib34","doi-asserted-by":"crossref","first-page":"1293","DOI":"10.1007\/s00467-013-2459-y","article-title":"Long-term side effects of treatment with mTOR inhibitors in children after renal transplantation","volume":"28","author":"Kranz","year":"2013","journal-title":"Pediatr. Nephrol."},{"issue":"Suppl.","key":"10.1016\/j.neuropharm.2018.08.002_bib35","article-title":"A phase 1 first-in-human (FIH) dose-escalation (DE) study of the oral dual PI3K\/mTOR inhibitor PQR309 in patients (pts) with advanced solid tumors: final DE results","volume":"33","author":"Kristeleit","year":"2015","journal-title":"J. Clin. Oncol."},{"key":"10.1016\/j.neuropharm.2018.08.002_bib36","doi-asserted-by":"crossref","first-page":"274","DOI":"10.1016\/j.cell.2012.03.017","article-title":"mTOR signaling in growth control and disease","volume":"149","author":"Laplante","year":"2012","journal-title":"Cell"},{"key":"10.1016\/j.neuropharm.2018.08.002_bib37","doi-asserted-by":"crossref","first-page":"45","DOI":"10.1016\/j.jneumeth.2015.03.009","article-title":"Animal models of temporal lobe epilepsy following systemic chemoconvulsant administration","volume":"260","author":"L\u00e9vesque","year":"2016","journal-title":"J. Neurosci. Meth."},{"key":"10.1016\/j.neuropharm.2018.08.002_bib38","doi-asserted-by":"crossref","first-page":"275","DOI":"10.1016\/j.neuron.2014.09.034","article-title":"The neurology of mTOR","volume":"84","author":"Lipton","year":"2014","journal-title":"Neuron"},{"key":"10.1016\/j.neuropharm.2018.08.002_bib39","doi-asserted-by":"crossref","first-page":"9742","DOI":"10.1074\/jbc.M111.304485","article-title":"Kinome-wide selectivity profiling of ATP-competitive mammalian target of rapamycin (mTOR) inhibitors and characterization of their binding kinetics","volume":"287","author":"Liu","year":"2012","journal-title":"J. Biol. Chem."},{"key":"10.1016\/j.neuropharm.2018.08.002_bib40","doi-asserted-by":"crossref","first-page":"7181","DOI":"10.18632\/oncotarget.12742","article-title":"Recent development of ATP-competitive small molecule phosphatidylinostitol-3-kinase inhibitors as anticancer agents","volume":"8","author":"Liu","year":"2017","journal-title":"Oncotarget"},{"key":"10.1016\/j.neuropharm.2018.08.002_bib41","doi-asserted-by":"crossref","first-page":"1868","DOI":"10.1007\/s11064-012-0797-y","article-title":"Time-dependent modulation of mitogen activated protein kinases and AKT in rat hippocampus and cortex in the pilocarpine model of epilepsy","volume":"37","author":"Lopes","year":"2012","journal-title":"Neurochem. Res."},{"key":"10.1016\/j.neuropharm.2018.08.002_bib42","doi-asserted-by":"crossref","first-page":"145","DOI":"10.1016\/0920-1211(88)90054-X","article-title":"Which animal models should be used in the search for new antiepileptic drugs? A proposal based on experimental and clinical considerations","volume":"2","author":"L\u00f6scher","year":"1988","journal-title":"Epilepsy Res."},{"key":"10.1016\/j.neuropharm.2018.08.002_bib43","doi-asserted-by":"crossref","first-page":"173","DOI":"10.1016\/0920-1211(90)90013-L","article-title":"The role of technical, biological and pharmacological factors in the laboratory evaluation of anticonvulsant drugs. I. The influence of administration vehicles","volume":"7","author":"L\u00f6scher","year":"1990","journal-title":"Epilepsy Res."},{"key":"10.1016\/j.neuropharm.2018.08.002_bib44","doi-asserted-by":"crossref","first-page":"79","DOI":"10.1016\/0920-1211(91)90075-Q","article-title":"The role of technical, biological and pharmacological factors in the laboratory evaluation of anticonvulsant drugs. II. Maximal electroshock seizure models","volume":"8","author":"L\u00f6scher","year":"1991","journal-title":"Epilepsy Res."},{"key":"10.1016\/j.neuropharm.2018.08.002_bib46","doi-asserted-by":"crossref","first-page":"147","DOI":"10.1016\/0014-2999(93)90768-D","article-title":"Profile of ucb L059, a novel anticonvulsant drug, in models of partial and generalized epilepsy in mice and rats","volume":"232","author":"L\u00f6scher","year":"1993","journal-title":"Eur. J. Pharmacol."},{"issue":"8","key":"10.1016\/j.neuropharm.2018.08.002_bib47","doi-asserted-by":"crossref","first-page":"12","DOI":"10.1111\/epi.12025","article-title":"How theories evolved concerning the mechanism of action of barbiturates","volume":"53","author":"L\u00f6scher","year":"2012","journal-title":"Epilepsia"},{"key":"10.1016\/j.neuropharm.2018.08.002_bib48","doi-asserted-by":"crossref","first-page":"757","DOI":"10.1038\/nrd4126","article-title":"New avenues for antiepileptic drug discovery and development","volume":"12","author":"L\u00f6scher","year":"2013","journal-title":"Nat. Rev. Drug Discov."},{"key":"10.1016\/j.neuropharm.2018.08.002_bib49","doi-asserted-by":"crossref","first-page":"157","DOI":"10.1016\/j.eplepsyres.2016.05.016","article-title":"Fit for purpose application of currently existing animal models in the discovery of novel epilepsy therapies","volume":"126","author":"L\u00f6scher","year":"2016","journal-title":"Epilepsy Res."},{"key":"10.1016\/j.neuropharm.2018.08.002_bib50","doi-asserted-by":"crossref","first-page":"1926","DOI":"10.1007\/s11064-016-2025-7","article-title":"The search for new screening models of pharmacoresistant epilepsy: is induction of acute seizures in epileptic rodents a suitable approach?","volume":"42","author":"L\u00f6scher","year":"2017","journal-title":"Neurochem. Res."},{"key":"10.1016\/j.neuropharm.2018.08.002_bib51","first-page":"782","article-title":"How significant is the difference between drug doses influencing the threshold for electroconvulsions?","volume":"57","author":"Luszczki","year":"2005","journal-title":"Pharmacol. Rep."},{"key":"10.1016\/j.neuropharm.2018.08.002_bib52","doi-asserted-by":"crossref","first-page":"991","DOI":"10.1517\/17460441.2013.800479","article-title":"Furthering the design and the discovery of small molecule ATP-competitive mTOR inhibitors as an effective cancer treatment","volume":"8","author":"Lv","year":"2013","journal-title":"Expet Opin. Drug Discov."},{"key":"10.1016\/j.neuropharm.2018.08.002_bib53","doi-asserted-by":"crossref","first-page":"181","DOI":"10.1016\/j.ejphar.2012.12.029","article-title":"FK506 binding proteins: cellular regulators of intracellular Ca2+ signalling","volume":"700","author":"MacMillan","year":"2013","journal-title":"Eur. J. Pharmacol."},{"key":"10.1016\/j.neuropharm.2018.08.002_bib54","doi-asserted-by":"crossref","first-page":"5422","DOI":"10.1523\/JNEUROSCI.0955-08.2008","article-title":"Response of a neuronal model of tuberous sclerosis to mammalian target of rapamycin (mTOR) inhibitors: effects on mTORC1 and Akt signaling lead to improved survival and function","volume":"28","author":"Meikle","year":"2008","journal-title":"J. Neurosci."},{"key":"10.1016\/j.neuropharm.2018.08.002_bib55","doi-asserted-by":"crossref","first-page":"1243","DOI":"10.1016\/j.drudis.2015.05.006","article-title":"Sirolimus and everolimus in kidney transplantation","volume":"20","author":"Moes","year":"2015","journal-title":"Drug Discov. Today"},{"key":"10.1016\/j.neuropharm.2018.08.002_bib56","doi-asserted-by":"crossref","first-page":"1093","DOI":"10.1038\/bjc.2012.368","article-title":"Safety, tolerability, pharmacokinetics and pharmacodynamics of AZD8055 in advanced solid tumours and lymphoma","volume":"107","author":"Naing","year":"2012","journal-title":"Br. J. Canc."},{"key":"10.1016\/j.neuropharm.2018.08.002_bib57","doi-asserted-by":"crossref","first-page":"91","DOI":"10.1007\/s40263-014-0223-x","article-title":"mTOR inhibition in epilepsy: rationale and clinical perspectives","volume":"29","author":"Ostendorf","year":"2015","journal-title":"CNS Drugs"},{"key":"10.1016\/j.neuropharm.2018.08.002_bib58","doi-asserted-by":"crossref","first-page":"226","DOI":"10.1684\/epd.2012.0532","article-title":"Animal models of drug-resistant epilepsy","volume":"14","author":"Potschka","year":"2012","journal-title":"Epileptic Disord."},{"key":"10.1016\/j.neuropharm.2018.08.002_bib59","doi-asserted-by":"crossref","first-page":"450","DOI":"10.1016\/j.eururo.2015.08.035","article-title":"A randomised phase 2 study of AZD2014 versus everolimus in patients with VEGF-refractory metastatic clear cell renal cancer","volume":"69","author":"Powles","year":"2016","journal-title":"Eur. Urol."},{"key":"10.1016\/j.neuropharm.2018.08.002_bib60","doi-asserted-by":"crossref","first-page":"281","DOI":"10.1016\/0013-4694(72)90177-0","article-title":"Modification of seizure activity by electrical stimulation: II. Motor seizure","volume":"32","author":"Racine","year":"1972","journal-title":"Electroencephalogr. Clin. Neurophysiol."},{"key":"10.1016\/j.neuropharm.2018.08.002_bib61","series-title":"Proceedings of the 107th Annual Meeting of the American Association for Cancer Research; 2017, Washington, DC","article-title":"Discovery and biological evaluation of PQR530, a highly potent dual pan-PI3K\/mTORC1\/2 inhibitor","author":"Rageot","year":"2017"},{"key":"10.1016\/j.neuropharm.2018.08.002_bib62","doi-asserted-by":"crossref","first-page":"18","DOI":"10.1093\/brain\/awh682","article-title":"Molecular and cellular mechanisms of pharmacoresistance in epilepsy","volume":"129","author":"Remy","year":"2006","journal-title":"Brain"},{"key":"10.1016\/j.neuropharm.2018.08.002_bib63","doi-asserted-by":"crossref","first-page":"a022780","DOI":"10.1101\/cshperspect.a022780","article-title":"Mechanisms of action of antiseizure drugs and the ketogenic diet","volume":"6","author":"Rogawski","year":"2016","journal-title":"Cold Spring Harb. Perspect. Med"},{"key":"10.1016\/j.neuropharm.2018.08.002_bib64","article-title":"The role of mTOR inhibitors in preventing epileptogenesis in patients with TSC: current evidence and future perspectives","author":"Schubert-Bast","year":"2018","journal-title":"Epilepsy Behav."},{"key":"10.1016\/j.neuropharm.2018.08.002_bib65","doi-asserted-by":"crossref","first-page":"36","DOI":"10.1097\/00007890-199707150-00008","article-title":"SDZ RAD, a new rapamycin derivative: pharmacological properties in vitro and in vivo","volume":"64","author":"Schuler","year":"1997","journal-title":"Transplantation"},{"key":"10.1016\/j.neuropharm.2018.08.002_bib66","doi-asserted-by":"crossref","first-page":"976","DOI":"10.1111\/ejn.12835","article-title":"Activation of mTOR signaling pathway is secondary to neuronal excitability in a mouse model of mesio-temporal lobe epilepsy","volume":"41","author":"Shima","year":"2015","journal-title":"Eur. J. Neurosci."},{"key":"10.1016\/j.neuropharm.2018.08.002_bib67","doi-asserted-by":"crossref","first-page":"319","DOI":"10.1016\/S0022-3565(25)05100-6","article-title":"Comparative assay of antiepileptic drugs in mice and rats","volume":"106","author":"Swinyard","year":"1952","journal-title":"J. Pharmacol. Exp. Therapeut."},{"key":"10.1016\/j.neuropharm.2018.08.002_bib68","doi-asserted-by":"crossref","first-page":"112","DOI":"10.1016\/j.neuroscience.2016.11.017","article-title":"Molecular neurobiology of mTOR","volume":"341","author":"Switon","year":"2016","journal-title":"Neuroscience"},{"key":"10.1016\/j.neuropharm.2018.08.002_bib69","doi-asserted-by":"crossref","first-page":"311","DOI":"10.1002\/ana.25149","article-title":"Mechanistic target of rapamycin complex 1 and 2 in human temporal lobe epilepsy","volume":"83","author":"Talos","year":"2018","journal-title":"Ann. Neurol."},{"key":"10.1016\/j.neuropharm.2018.08.002_bib70","doi-asserted-by":"crossref","first-page":"3133","DOI":"10.1158\/1078-0432.CCR-13-1759","article-title":"P-glycoprotein, CYP3A, and plasma carboxylesterase determine brain and blood disposition of the mTOR Inhibitor everolimus (Afinitor) in mice","volume":"20","author":"Tang","year":"2014","journal-title":"Clin. Canc. Res."},{"key":"10.1016\/j.neuropharm.2018.08.002_bib71","doi-asserted-by":"crossref","first-page":"48","DOI":"10.2174\/1874467208666150519113541","article-title":"FK506-Binding proteins and their diverse functions","volume":"9","author":"Tong","year":"2015","journal-title":"Curr. Mol. Pharmacol."},{"key":"10.1016\/j.neuropharm.2018.08.002_bib72","series-title":"Epilepsy. A Comprehensive Textbook","first-page":"1469","article-title":"Screening of new compounds and the role of the pharmaceutical industry","author":"White","year":"2008"},{"key":"10.1016\/j.neuropharm.2018.08.002_bib73","doi-asserted-by":"crossref","first-page":"219","DOI":"10.1016\/S0920-1211(98)00008-4","article-title":"Frontal versus transcorneal stimulation to induce maximal electroshock seizures or kindling in mice and rats","volume":"30","author":"Wlaz","year":"1998","journal-title":"Epilepsy Res."},{"key":"10.1016\/j.neuropharm.2018.08.002_bib74","doi-asserted-by":"crossref","first-page":"27","DOI":"10.1111\/j.1528-1167.2009.02341.x","article-title":"Mammalian target of rapamycin (mTOR) inhibition as a potential antiepileptogenic therapy: from tuberous sclerosis to common acquired epilepsies","volume":"51","author":"Wong","year":"2010","journal-title":"Epilepsia"},{"key":"10.1016\/j.neuropharm.2018.08.002_bib75","doi-asserted-by":"crossref","first-page":"40","DOI":"10.4103\/2319-4170.110365","article-title":"Mammalian target of rapamycin (mTOR) pathways in neurological diseases","volume":"36","author":"Wong","year":"2013","journal-title":"Biomed. J."},{"key":"10.1016\/j.neuropharm.2018.08.002_bib76","doi-asserted-by":"crossref","first-page":"35","DOI":"10.1016\/j.neuropharm.2015.05.008","article-title":"Rapamycin prevents cadmium-induced neuronal cell death via targeting both mTORC1 and mTORC2 pathways","volume":"97","author":"Xu","year":"2015","journal-title":"Neuropharmacology"},{"key":"10.1016\/j.neuropharm.2018.08.002_bib77","doi-asserted-by":"crossref","first-page":"1109","DOI":"10.1517\/13543776.2011.584871","article-title":"Recent advances in the discovery of small-molecule ATP competitive mTOR inhibitors: a patent review","volume":"21","author":"Zask","year":"2011","journal-title":"Expert Opin. Ther. Pat."},{"key":"10.1016\/j.neuropharm.2018.08.002_bib78","doi-asserted-by":"crossref","first-page":"444","DOI":"10.1002\/ana.21331","article-title":"Rapamycin prevents epilepsy in a mouse model of tuberous sclerosis complex","volume":"63","author":"Zeng","year":"2008","journal-title":"Ann. Neurol."},{"key":"10.1016\/j.neuropharm.2018.08.002_bib79","doi-asserted-by":"crossref","first-page":"6964","DOI":"10.1523\/JNEUROSCI.0066-09.2009","article-title":"The mammalian target of rapamycin signaling pathway mediates epileptogenesis in a model of temporal lobe epilepsy","volume":"29","author":"Zeng","year":"2009","journal-title":"J. Neurosci."},{"key":"10.1016\/j.neuropharm.2018.08.002_bib80","doi-asserted-by":"crossref","first-page":"2463","DOI":"10.1007\/s00213-015-3884-3","article-title":"Modafinil and its metabolites enhance the anticonvulsant action of classical antiepileptic drugs in the mouse maximal electroshock-induced seizure model","volume":"232","author":"Zolkowska","year":"2015","journal-title":"Psychopharmacology (Berlin)"}],"container-title":["Neuropharmacology"],"original-title":[],"language":"en","link":[{"URL":"https:\/\/api.elsevier.com\/content\/article\/PII:S0028390818304684?httpAccept=text\/xml","content-type":"text\/xml","content-version":"vor","intended-application":"text-mining"},{"URL":"https:\/\/api.elsevier.com\/content\/article\/PII:S0028390818304684?httpAccept=text\/plain","content-type":"text\/plain","content-version":"vor","intended-application":"text-mining"}],"deposited":{"date-parts":[[2025,7,6]],"date-time":"2025-07-06T06:05:26Z","timestamp":1751781926000},"score":1,"resource":{"primary":{"URL":"https:\/\/linkinghub.elsevier.com\/retrieve\/pii\/S0028390818304684"}},"subtitle":[],"short-title":[],"issued":{"date-parts":[[2018,9]]},"references-count":79,"alternative-id":["S0028390818304684"],"URL":"https:\/\/doi.org\/10.1016\/j.neuropharm.2018.08.002","relation":{},"ISSN":["0028-3908"],"issn-type":[{"value":"0028-3908","type":"print"}],"subject":[],"published":{"date-parts":[[2018,9]]},"assertion":[{"value":"Elsevier","name":"publisher","label":"This article is maintained by"},{"value":"The novel, catalytic mTORC1\/2 inhibitor PQR620 and the PI3K\/mTORC1\/2 inhibitor PQR530 effectively cross the blood-brain barrier and increase seizure threshold in a mouse model of chronic epilepsy","name":"articletitle","label":"Article Title"},{"value":"Neuropharmacology","name":"journaltitle","label":"Journal Title"},{"value":"https:\/\/doi.org\/10.1016\/j.neuropharm.2018.08.002","name":"articlelink","label":"CrossRef DOI link to publisher maintained version"},{"value":"article","name":"content_type","label":"Content Type"},{"value":"\u00a9 2018 Elsevier Ltd. All rights reserved.","name":"copyright","label":"Copyright"}]}}